Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical Cancer

Unknown Phase 2 NCT04693234

Study Description

This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous treatments. The study included two groups and took place at multiple medical centers.

Study Details

Registry ID:
NCT04693234
Conditions:
Cervical Cancer
Phase:
Phase 2
Target Enrollment:
178 participants
Start Date:
Age Range:
18–999 years
Gender:
Female
Healthy Volunteers:
No

Study Locations (77 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →